Outsourcing

Is the contract-only CMO an endangered species?

A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.

CROs are keeping pace with the increased globalization of the biopharmaceutical/pharmaceutical industry through a combination of acquisitions, partnerships, and select investments.

In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.

Preferred-provider relationships are transforming the bio/pharmaceutical industry.

When speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.

Adherence to GMP in API manufacturing is crucial in determining the safety of drug products.

Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends.

Will international biomanufacturing outsourcing become mainstream in this decade?

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

The procurement organization rethinks sourcing for maximum efficiency and results.

Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

To support global stability practices, fundamental basics must be in place.

Patheon will acquire softgel-specialist company Banner Pharmacaps, based in North Carolina in the US, for $255 million

Consider the time and expertise needed to maintain regulatory compliance and perform stability testing.

Consider these tools and strategies for optimizing the manufacturing process.

Today's pharmaceutical companies are striving to reduce costs and maximize efficiencies, and must make decisions on the best way to deploy their limited resources.

Working together affords many unseen opportunities for pharmaceutical innovation.

Measuring the size of the market for contract manufacturing services requires a careful hand.

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.

The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.

An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.

The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.

The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.